Baird Maintains Outperform on Watsco, Raises Price Target to $323

Baird analyst David Manthey maintains Watsco (NYSE:WSO) with a Outperform and raises the price target from $313 to $323.

byBenzinga Newsdesk

July 27, 2022

1 minute read

Baird analyst David Manthey maintains Watsco (NYSE:WSO) with a Outperform and raises the price target from $313 to $323.

Elon Musk’s Starship Launch To Cost Just $10 Per Kg: How It Compares With ‘Heavy Lifters’ From 5 Decades Ago

By Shanthi Rexaline

Today, 6:08 AM

The Tesla Inc. (NASDAQ: TSLA) Elon Musk-owned SpaceX’s Starship is a launch vehicle the company is developing and testing for

TSLA

Evercore ISI Group Maintains Outperform on CubeSmart, Lowers Price Target to $53

By Benzinga Newsdesk

Today, 6:08 AM

Evercore ISI Group analyst Steve Sakwa maintains CubeSmart (NYSE:CUBE) with a Outperform and lowers the price target from $54 to $53.

CUBE

Analysts Expressed Optimism Over Autodesk’s Upcoming Results Citing Robust Demand, Digitization, Easing Macros

By Anusuya Lahiri

Today, 6:08 AM

Mizuho analyst acknowledged that several significant large-cap software vendors are due to report July quarter results over the next few weeks. Following an extended sell-off, software and the broader market have significantly rallied in recent weeks.

ADSK

News

Burning Rock, and IMPACT Therapeutics Announced Global Strategic Partnership for Companion Diagnostics Development

By Charles Gross

Today, 6:08 AM

Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of synthetic lethality.

BNR

Baird Maintains Outperform on Watsco, Raises Price Target to $323

Related Posts

Elon Musk’s Starship Launch To Cost Just $10 Per Kg: How It Compares With ‘Heavy Lifters’ From 5 Decades Ago

Evercore ISI Group Maintains Outperform on CubeSmart, Lowers Price Target to $53

Analysts Expressed Optimism Over Autodesk’s Upcoming Results Citing Robust Demand, Digitization, Easing Macros

Burning Rock, and IMPACT Therapeutics Announced Global Strategic Partnership for Companion Diagnostics Development